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cense.Abstract Introduction: Adnexal masses are a common clinical problem and considered as the
leading indication for gynecological surgery. The ovary and adnexal structures are relatively difﬁ-
cult to image with any technology. Magnetic resonance spectroscopy (MRS) can detect metabolic
changes. As molecular changes often precede morphologic alterations, sensitivity is expected to
improve by MRS. Diffusion weighted magnetic resonance imaging (DW-MRI) is sensitive to molec-
ular diffusion which is due to random microscopic translational motion of molecules (known as
Brownian motion). In the event of morphologic evaluation of cystic ovarian tumors, whether
benign or malignant, DW-MR imaging and calculated apparent diffusion coefﬁcient (ADC) values
would be useful for evaluation.
Purpose: The aim of this study is to evaluate the role of diffusion MRI & proton magnetic
resonance spectroscopy (H-MRS) in diagnosis of ovarian neoplasms.partment of Radiodiagnosis,
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100 L. El sorogy et al.Subjects and methods: This study included 20 patients, their ages ranged from 20 to 72 years. In all
cases, diagnosis was proven by surgical and pathological examination. Trans-abdominal ultrasound
(n= 20) and trans-vaginal ultrasound (n= 11) were included in our routine protocol to obtain
baseline information preceding MR examination. The routine MR examination protocol included:
T1WI, T2WI, and post contrast fat suppressed T1WI. Diffusion weighted imaging (DWI) was done
to all patients at b0, b500, b1000 and ADC values were calculated. MRS was performed in all cases
using multi-voxel point resolved surface coil spectroscopy (PRESS sequence) for volume localiza-
tion.
Results: Fourteen cases (70%) had benign ovarian masses while the remaining six cases (30%) had
malignant masses. High lipid peak was detected in all three cases of mature cystic teratoma. All
cases of simple serous cysts showed choline and creatine signals that were higher than the average
noise level but lower than the two fold higher noise level. Sharp choline peak was detected in all
malignant ovarian masses (except a case of metastases under chemotherapy) as well as the case
of ﬁbroma. Creatine signal was detected in all benign and malignant masses except two cases of
mature cystic teratoma and cases of endometrioma. Lactate signal was detected only in cases of
hemorrhagic cysts, mature cyst teratoma and one case of endometrioma and not obtained in any
of malignant lesions except dysgerminoma. High NAA signal was detected in dysgerminoma and
all three cases of mature cystic teratomas. The mean Cho/Cr ratio was signiﬁcantly higher in malig-
nant than benign ovarian masses (<0.05), there was no signiﬁcant difference in mean and lowest
ADC values between malignant and benign lesions.
Conclusion: Proton MRS using Cho/Cr ratio added useful information for the diagnosis of differ-
ent ovarian neoplasms. Direct visual assessment of DWI of ovarian lesions is not useful in differ-
entiating benign from malignant ovarian lesions; determining the threshold of the ADC for
diagnosing cystic ovarian tumors is difﬁcult because of their large variance. Further experience with
a larger and more biologically variable range of tumors is recommended.
 2012 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Adnexal masses are a common clinical problem and consid-
ered as the leading indication for gynecological surgery [1].
The overall risk of a primary ovarian neoplasm that is malig-
nant increases from 13% in premenopausal women to 45%
following menopause [2].
The ovary and adnexal structures are relatively difﬁcult to
image with any technology [3]. Transvaginal ultrasound
(TVS) remains the investigation most commonly performed
ﬁrst for the investigation of ovaries. Magnetic resonance
(MR) imaging can yield additional information, MR imaging
is capable of diagnosing adnexal masses as cystic or solid,
and can characterize the components as ﬂuid, fatty, or hemor-
rhagic [3]. However, it has poor speciﬁcity [4].
Molecular imaging through magnetic resonance spectros-
copy (MRS) can detect metabolic features characteristic of
malignancy. As molecular changes often precede morpho-
logic alterations, sensitivity is expected to improve by
MRS. This kind of molecular imaging is becoming widely
accepted as a technique for an early detection of pathologi-
cal changes of different body organs by identifying key
changes for the emergence and progression of cancer on
the molecular level [4].
Diffusion weighted magnetic resonance imaging (DW-
MRI) is sensitive to molecular diffusion which is due to ran-
dom microscopic translational motion of molecules (known
as Brownian motion). In the event of morphologic evaluation
of cystic ovarian tumors, whether benign or malignant, DW-
MR imaging and calculated apparent diffusion coefﬁcient
(ADC) values would be useful to evaluate the cystic content
of ovarian lesions [5].The purpose of this study is to evaluate the role of diffusion
MRI and magnetic resonance spectroscopy in the diagnosis of
ovarian neoplasms.
2. Subjects and methods
Our study included 20 female patients, their age ranged from
20 to 72 years with mean age 44.3 years. They were referred
from Gynecology unit of Obstetrics and Gynecology Depart-
ment, Mansoura University Hospital. They had symptoms
and or signs suggestive of adnexal masses, they were taken in
a consecutive manner after exclusion of cases of adnexal
masses outside the ovaries and those with symptoms or signs
suggestive of inﬂammation. The clinical presentations were
pain (n= 18), pelvic-abdominal swelling (n= 5), bleeding
(n= 4), primary infertility (n= 3), and hematemsis and epi-
gastric pain (n= 1). As primary diagnosis trans-abdominal
ultrasound (n= 20) and trans-vaginal ultrasound (n= 11)
were included in our routine protocol to obtain baseline infor-
mation preceding MR examination. It was performed using
Medison Sonoace 8800 apparatus. In all cases, the diagnosis
was proven by surgical and pathological examination.
MR examination was done for all cases using 1.5 Tesla sys-
tem (Siemens AG Symphony, Germany) with a body coil as a
RF transmitter and a signal receiver. The routine MR exami-
nation protocol in our study included: T1WI (TR/TE = 700–
750/10–20), T2WI (TR/TE = 3000–3700/90–110), and post
contrast fat suppressed T1WI with slice thickness (5–10 mm),
intersection gap (1–2 mm) ﬁeld of view (20–40 cm) and matrix
size (128 · 256). Diffusion weighted imaging (DWI) was done
routinely to all patients at b0, b500, b1000 and ADC values
were calculated. MRS was performed in all cases using
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sequence) for volume localization with TE (135 and 270 ms)
to detect metabolites with long and intermediate T2 relaxation
times such as N-acetyl aspartate (NAA), choline, creatine and
lactate. The region of interest (ROI) for MRS measurement
was placed at the center of the cystic part or solid part of tu-
mors to avoid contamination signals from peripheral tissues.
Patient spectra were interpreted qualitatively by inspection of
the peaks. Another approach is the quantitative approach
using the integral ratios (Cho/Cr). Concentrations of Cho,
Cr, lipid and lactate were evaluated. The metabolite peak areas
were classiﬁed into three classes, in comparison with the noise
level by visual estimation: that is, twofold higher than the aver-
age noise level (++), higher than the average noise level but
lower than the twofold higher noise level (+), and the same
as the average noise level (). The classiﬁcation of metabolite
peaks area in this study was performed according to the tech-
nique described by Okada et al. [16].
The statistical analysis of data was done by using SPSS pro-
gram statistical package for social science version 10 and excel
program. First, mean and standard deviation of the Cho/Cr
ratios, ADC values of the solid portions and ADC value of
the cystic portions of examined masses were calculated. Then,
t test was done to show if there was signiﬁcant difference in the
Cho/Cr ratios, ADC values between benign and malignant
ovarian tumors. The P value of less than 0.05 was considered
signiﬁcant.
3. Results
Among 20 cases included in this study, fourteen cases (70%)
had benign ovarian masses while the remaining six cases
(30%) had malignant ovarian masses. The pathological entities
of the studied cases are listed in Table 1.
The metabolite levels measured in cases of benign and
malignant ovarian masses are listed in Tables 2 and 3
respectively.
From Tables 2 and 3, high lipid peak was detected in all
three cases of mature cystic teratoma. This reﬂects fatty com-
ponent of the tumor. All cases of simple serous cysts showed
choline and creatine signals that were higher than the average
noise level but lower than the twofold higher noise level. Sharp
choline peak was detected in all malignant ovarian masses.
Sharp choline was detected also in cases of ﬁbroma
although benign. Creatine signal was detected in all benignTable 1 Pathological entities of the studied cases.
Pathology Number of
patients
Benign (n= 14) Simple serous cyst 3
Hemorrhagic cyst 2
Mature cystic teratoma 3
Endometrioma 3
Fibroma 2
Mucinous cystadenoma 1
Malignant (n= 6) Mucinous cystadenocarcinoma 2
Serous cystadenocarcinoma 1
Poor diﬀerentiated adenocarcinoma 1
Dysgerminoma 1
Metastases 1and malignant masses except two cases of mature cystic
teratoma and cases of endometrioma. Lactate signal was de-
tected only in cases of hemorrhagic cyst, mature cyst teratoma
and one case of endometrioma and not obtained in any of the
malignant lesions except dysgerminoma. Our study also de-
tected NAA signal in dysgerminoma and all three cases of ma-
ture cystic teratomas.
The mean Cho/Cr ratios of the malignant ovarian masses
were signiﬁcantly higher than those of benign ovarian masses
(p value 0.004). The sensitivity of Cho/Cr ratio in differentiat-
ing benign from malignant ovarian lesions was 0.83, speciﬁcity
0.82, accuracy 0.82, predictive value of +ve result is 0.82 and
predictive value of ve result 0.83.
The ADC values calculated in benign and malignant cases
are shown in Tables 4 and 5, respectively.
There was no signiﬁcant difference in mean and lowest
ADC values between malignant and benign lesions, p 0.059.
4. Discussion
Ovarian cancer has the highest mortality rate of all gyneco-
logic malignant tumors. Nearly two thirds of all ovarian carci-
nomas have progressed to disease stage III or IV at the time of
ﬁrst diagnosis because they may remain clinically asymptom-
atic for extended periods. This fact underscores the importance
of the early detection of these tumors and of the correct deter-
mination of epithelial ovarian tumors of low malignant poten-
tial (borderline tumors) [6]. Determining whether an ovarian
tumor is malignant or benign before operation, especially
when the tumor has both solid and cystic components, is often
difﬁcult. Excessive surgical procedures such as bilateral ooph-
orectomy with or without hysterectomy have sometimes been
performed in patients with benign ovarian tumor because the
preoperative diagnosis was inaccurate [7]. Preoperative diag-
nosis would allow surgical skills to be brought to the operating
theater for the beneﬁt of patients receiving primary surgical
intervention [8].
Proton (H1) magnetic resonance (MR) spectroscopy is not
a new technology, having been used to provide biochemical
information about biologic tissues for over 30 years [9]. It gives
information related to cellular integrity, cell proliferation or
degradation and energy metabolism of tissues [10]. In the re-
cent period, striking attention has been paid in leading investi-
gative clinical journals to in vivo MRS as a potentially key
non-invasive modality for cancer diagnostics [4]. As it provides
both anatomic and metabolic information, especially since
metabolic changes can often precede anatomic/morphologic
alterations [11].
MRS can provide vital information when biopsy is not pos-
sible due to potential morbidity. This is particularly the case in
brain tumor diagnostics, where MRS is virtually irreplaceable
[4]. As for adnexal lesions, however, the use of MRS in in vivo
studies has been limited due to respiratory and bowel move-
ments. Recently the usefulness of proton MRS in uterine cer-
vix cancer, endometrial carcinoma, benign and malignant
ovarian tumors has also been recognized [12]. MRS provides
powerful means in measuring steady-state levels and ﬂuxes of
metabolites in the pathways responsible for the biosynthesis
and catabolism of phosphatidylcholine, the major phospho-
lipid of cell membranes. Choline phospholipid metabolism in
ovarian cancer has received only limited attention despite
Table 2 Metabolite levels in the fourteen studied benign cases.
Histopathology No. of patients Metabolites detected Mean Cho/Cr ratio
Cho Cr Lac NAA Lipid
Simple serous cyst 3 +(n= 3) +(n= 3)  +(n= 2)  1.1
Hemorrhagic cyst 2 +(n= 2) +(n= 2) + (n= 2)   0.8
Mature cystic teratoma 3 +(n= 1) +(n= 1) + (n= 3) +(n= 3) +(n= 3) 0.9
Endometrioma 3   + (n= 1) +(n= 1)  
Fibroma 2 +(n= 2) +(n= 2)    1.5
Mucinous cyst adenoma 1 + +    1
+ Higher than the average noise level but lower than the twofold higher noise level.
 Same as the average noise level.
Table 3 The metabolite level in six studied cases of malignant ovarian masses.
Histopathology No. of patients Metabolites detected Cho/Cr ratio
Cho Cr Lac NAA Lipid
Serous cyst adenocarcinoma 1 + +    2
Mucinous cyst adenocarcinoma 2 +(n= 2) +(n= 2)    1.5
Poor diﬀerentiated adenocarcinoma 1 + +    1.5
Dysgerminoma 1 ++ + + +  2.5
Metastases (Krukenberg tumor) 1 + +    1
+ Higher than the average noise level but lower than twofold higher noise level.
++ Twofold higher than the average noise level.
 Same as the average noise level.
Table 4 Calculated ADC in fourteen cases of benign ovarian
masses.
Histopathology ADC values
Solid parts Cystic parts
Simple serous cyst – 303
Simple serous cyst – 295
Simple serous cyst – 286
Hemorrhagic cyst – 159
Hemorrhagic cyst 175 336
Mature cystic teratoma 199 156
Mature cystic teratoma 98 179
Mature cystic teratoma – 147
Endometrioma 113 293
Endometrioma 115 274
Endometrioma 121 296
Fibroma – 198
Fibroma 103 –
Mucinous cystadenoma 145 254
Table 5 Calculated ADC in six cases of malignant ovarian
masses.
Histopathology (malignant) ADC values
Solid parts Cystic parts
Serous cyst adenocarcinoma 134 364
Mucinous cyst 254 465
Adenocarcinoma mucinous cyst
adenocarcinoma
296 494
Poor diﬀerentiated adenocarcinoma 264 –
Dysgerminoma 127 208
Metastases (Krukenburg tumor) 123 –
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ovary tumors and biopsies and accumulation of phosphocho-
line in ovarian carcinoma cell lines [13].
In this study, we used TE (135 and 270) to detect metabo-
lites with different relaxation times as metabolites as NAA,
Choline and creatine appear with long TE. Lactate for exam-
ple projects above the baseline with TE 270 whereas at a TE
of 135 ms, the lactate doublet is inverted below the baseline.
So, the use of both relaxation times helps in differentiating it
from other nearby metabolites. Also, lipid peaks are normallymuch less intense/absent at a TE of 270 ms than in shorter
relaxation times.
4.1. Choline
It is a cell membrane marker observed at 3.2 ppm. It plays an
important role in the structure and biochemical activity of cell
membranes. Increased choline probably reﬂects increased
membrane synthesis and/or increased number of cells [14]
Some authors [12,15,16] have reported that Cho peak was de-
tected in all cases of solid tumor or solid parts in cystic tumors,
and considered that the Cho signal of solid parts in pelvic tu-
mors reﬂects activation of membrane metabolism of tumor
cells. However, the Cho peak was found even in benign tumors
and could not be used for the differential diagnosis between
benign and malignant tumors. Our study revealed sharp cho-
line peak in ovarian ﬁbroma, mucinous cystadenoma as well
as dysgerminoma and so Cho peak could not help in the differ-
ential diagnosis (Figs. 1 and 2).
Fig. 1 Proton MRS in a case of ﬁbroma. A sharp Cho peak is observed clearly (TR = 1300 msec, TE = 135 msec).
Fig. 2 Proton MRS in a case of dysgerminoma. A sharp Cho peak is observed clearly (TR = 1300 msec, TE = 135 msec).
Fig. 3 Proton MRS in a case of mature cystic teratoma. A lactate peak is observed clearly (TR = 1300 msec, TE = 135 msec).
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It is the end-product of anaerobic glycolysis and appears at
1.3 ppm. The presence of lactate generally indicates that the
normal cellular oxidative respiration mechanism is no longer
in effect, and carbohydrate catabolism is taking place [14].
Previous studies [12,16] demonstrated that lactate signals were
detected in some cases of benign tumor, and all cases of malig-
nant tumors showed lactate and tended to form higher peaks
than benign tumors. Another study [15] has reported that lac-
tate signals of malignant ovarian cystic mass were signiﬁcantly
higher than those of benign ovarian cystic mass. Therefore,
when there are no lactate signals detected, there appears to
be a very low probability of malignancy and the lactate signal
might be used as an index of differentiation among malignant
and benign tumors. In our study, a very striking ﬁnding is that
lactate signal was detected in all benign lesions except simpleserous cysts and mucinous cystadenoma, and not obtained in
any of malignant lesions except dysgerminoma (Figs. 2 and 3).
4.3. Lipids
Visible lipids in normal tissues are bound to macromolecule
membranes. Therefore, lipids are physiologically not detect-
able in the spectrum of healthy human by MRS. Some patho-
logic conditions yield detectable lipid signals at 0.9 and
1.3 ppm [11]. In our study high lipid peak in the dermoid cysts
was a characteristic ﬁnding reﬂecting a high content of fatty
component (Fig. 3), the condition that is in agreement with
Okada et al. [16]. Our case of ﬁbroma was pathologically pro-
ven to be associated with massive infarction necrosis, with the
voxel placed in the area of necrosis, high lipid peak was de-
tected and this may be due to disruption of macromolecules
in the cell membrane (Fig. 1).
Fig. 4 Proton MRS of a case of simple serous cyst revealed Cho, NAA and lactate peaks. (TR = 1300, TE = 270).
Fig. 5 Bilateral poor differentiated adenocarcinoma in a 40 year-old woman. DWI (b1000) showed restricted diffusion with mean
ADC= 234 · 103 mm2/sec.
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It is found in high concentration exclusively in the nervous sys-
tem [17]. NAA is resonating at 2.0 ppm, it is called neuronal
marker [18]. Some authors [19,20] detected NAA metabolites
in spectroscopy analysis of both solid and cystic parts of the
mucinous cystadenoma. Another study [21] with in vitro
MRS reported NAA signals in cyst ﬂuid from serous cystade-
nomas of the ovary. It has been proposed that the NAA system
is a molecular water pump [22]. Molecular water pumps are
normal biochemical system existing at compartmental bound-
ary of living cells where they actively pump water against its
gradient [23]. Our study also detected NAA signal in all cases
of mature cystic teratomas (Fig. 3), denoting the presence of
neural element (ectodermal tissue). Cases of simple follicular
cysts (Fig. 4) revealed also NAA peaks although devoid of
neural tissue, and were thought to be used by the cells to pump
water against its gradients (water pump). Another explanation
was suggested by Kolwijck et al. [24] who concluded that both
NAA and N-acetyl groups from glycoproteins and/or glycolip-
ids may contribute to the delta 2.0–2.1 ppm resonance complex
in the ovarian cyst ﬂuid.
4.5. Choine/creatine ratio
Elevation of Choline/Cr ratio has been previously noted in
studies of human cancers [25,26]. In our study, we found that
the mean Cho/Cr ratio of malignant ovarian masses is signiﬁ-
cantly higher than that of benign ovarian masses (p 0.004), the
same was reported by Stanwell et al. [27].Pinker et al. [28] reported that the application of 1H-MRS in
the assessment and monitoring of cancerous disease can be lim-
ited by several factors. One limitation is the size of the voxel re-
quired to obtain an adequate signal-to-noise (SNR) ratio to
detect the presence of malignancy. In very small lesions, the
sensitivity of 1H-MRSI to discriminate between benign and
malignant lesions deteriorates due to partial volume effects.
To overcome this limitation, 1H-MRSI could be performed
at higher ﬁeld strengths with increased SNR and smaller voxel
sizes. Another limitation of 1H-MRS is of an intrinsic biochem-
ical origin. At the clinically used ﬁeld strengths of 1.5 and 3 T,
the detection of metabolites other than Cho that are indicative
of cancer is limited due to the much lower concentrations of
these compounds (0.01 mol/L for Cho vs. 0.00001 mol/L or
lower for other tumor associated compounds). A solution to
this problem could be the utilization of higher ﬁeld strengths
(7 T or higher) and phosphorus MR spectroscopy (31PMRSI),
as 31P MRS can detect some of these compounds and is more
sensitive at higher ﬁeld strengths.
Technical advances in diffusion-weighted imaging (DWI)
greatly enhanced the clinical value of magnetic resonance
imaging (MRI) of the body. DWI can provide excellent tissue
contrast based on molecular diffusion and may be able to
demonstrate malignant tumors (Fig. 5). Quantitative measure-
ment of the apparent diffusion coefﬁcient (ADC) may be valu-
able in distinguishing between malignant and benign lesions.
Although the ADC can help to differentiate between normal
and cancerous tissues in the uterine cervix and endometrium,
its utility may be limited by the large overlap of the uterine
myometrium and ovaries. On the other hand, the ADC may
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arterial embolization (UAE), chemotherapy and/or radiation
therapy. In patients with ovarian cancer, DWI demonstrates
high intensity not only at the primary cancer site but also in
disseminated peritoneal implants. When added to conventional
MRI ﬁndings, DWI and ADC values provide additional infor-
mation and DWI may play an important role in the diagnosis
of patients with gynecological diseases [29].
In this study, ADC measurements did not contribute to dif-
ferentiating benign from malignant ovarian masses. The same
ﬁndings were reported in previous studies [30–32]. Fujii et al.
[30] added that this knowledge is essential to avoid misinter-
pretation in the diagnosis of ovarian lesions.
Also, Takeuchi et al. [32] reported that low intensity on
DWI with high ADC may suggest benign lesions; however, it
may be occasionally difﬁcult to differentiate benign and malig-
nant lesions only on the basis of DWI. The same was men-
tioned by Bakir et al. [33] who stated that in their study,
there was no signiﬁcant difference between the ADC values
of the malignant and benign lesions in either the adnexal or
ovarian lesions and when signal intensities on DWI were com-
pared, malignant lesions had higher values than the benign le-
sions in both the adnexal and ovarian lesions.
This study has many limitations, ﬁrst of all is the small
number of malignant pelvic tumors studied, other limitations
include the less favorable anatomical position of the ovary be-
cause of the small size and motion of this organ, and the very
few studies concerned in this issue.
From this study, we concluded that proton MRS using
Cho/Cr ratio added useful information for differentiating be-
nign from malignant ovarian neoplasm, but further clinical
studies and in vitro conﬁrmation are recommended to establish
the usefulness of proton MRS in adnexal masses.
We also concluded that the direct visual assessment of DWI
of ovarian lesions is not useful in differentiating benign from
malignant ovarian lesions; however, DWI plays a complemen-
tary role in detecting the solid components of malignant le-
sions. Determining the threshold of the ADC for diagnosing
cystic ovarian tumors is difﬁcult because of their large variance.
We recommend further investigation involving a large num-
ber of cases, more biologically variable range of tumors and
further efforts to elucidate the value of integrating the current
imaging modalities with the metabolic information provided
by H1-MRS, to improve the strategies of the noninvasive pre-
operative diagnosis and also to establish the limits of speciﬁcity
and the precise role of MR-DWI in differentiating cystic ovar-
ian pathologies. Thus, the ﬁnal clinical utility of these tech-
niques is determined.
Reference
[1] Bazot M, Slaba J, Naggara I, et al.. MR imaging compared with
intraoperative frozen-section examination for the diagnosis of
adnexal tumors: correlation with ﬁnal histology. Eur Radiol
2006;16:2687–99.
[2] Curtin J. Management of the adnexal mass. Gynecol Oncol
1999;55:42–6.
[3] Pretorius E, Scott M, Eric K, et al.. Magnetic resonance imaging
of the ovary. Top Magn Reson Imaging 2001;12:131–46.
[4] Belki´c D, Belki´c K. The general concept of signal–noise separa-
tion (SNS): mathematical aspects and implementation in magnetic
resonance spectroscopy. J Mathemat Chem 2008;44:884–912.[5] Moteki T, Ishizaka H. Evaluation of cystic ovarian lesions using
apparent diffusion coefﬁcient calculated from turbo FLASH MR
imaging. Bri J Radiol 1998;71:612–20.
[6] Rieber A, Nu¨ssle K, Stohr I, et al.. Preoperative diagnosis of
ovarian tumors with MR imaging: comparison with transvaginal
sonography, positron emission tomography, and histologic ﬁnd-
ings. Am J Radiol 2001;177:123–9.
[7] Kim S, Kim S, Yang D, et al.. Unusual causes of tuboovarian
abscess: CT and MR imaging ﬁndings. RadioGraphics
2004;24:1575–89.
[8] Mountford C, Stanwell P, Ferrier A, et al.. In vivo spectroscopy
and imaging of the ovary in vivo at 3 Tesla and spectroscopy on
biopsy at 8.5 Tesla. J Wom Imaging 2005;7:71–6.
[9] Bartella L, Huang W. Proton (1H) MR spectroscopy of the
breast. Radiographics 2007;27:241–52.
[10] Sarac K, CeliK O, Hascalik S, et al.. In vivo proton magnetic
resonance spectroscopy in the evaluation of the endometrium.
Acta Obstet Gynecol Scand 2004;83:751–7.
[11] Payne G, Leach M. Applications of magnetic resonance spectros-
copy in radiotherapy treatment planning. Br J Radiol
2006;79:16–24.
[12] Hascalik S, Celik O, Sarac K, et al.. Metabolic changes in pelvic
lesions: ﬁndings at proton MR spectroscopic imaging. Gynecol
Obstet Invest 2005;60:121–7.
[13] Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline
phospholipid metabolism in ovarian tumor progression. Cancer
Res 2005;65:9369–76.
[14] Maheshwari S, Fatterpekar G, Castillo M, et al.. Proton MR
spectroscopy of the brain. Semin Ultrasound CT
2000;6:434–51.
[15] Massuger L, Vierzen P, Engelke U, et al. H1-magnetic resonance
spectroscopy: a new technique to discriminate benign from
malignant ovarian tumor. Cancer 1998;82:1726–30.
[16] Okada T, Harada M, Matsuzaki K, et al. Evaluation of female
intrapelvic tumors by clinical proton MR spectroscopy. J Magn
Reson 2001;13:912–7.
[17] Xu S, Yang J, Shen J. Measuring N-acetyl aspartate synthesis
in vivo using proton magnetic resonance spectroscopy. J Neurosci
Methods 2008;172:8–12.
[18] Miller B. A review of chemical issue in H1NMRS: NAA, Creatine
and choline. NMR Biomed 1992;4:47–52.
[19] Hascalik S, Celik O, Sarac K, et al. Clinical signiﬁcance of N-
acetyl-L-aspartate resonance in ovarian mucinous cystadenoma.
Int J Gynecol Cancer 2006;16:423–47.
[20] Takeuchi M, Matsuzaki K, Harada M, et al. Preliminary
observations and clinical value of N-acetyl resonances in ovarian
tumours using in vivo proton MR spectroscopy at 3 T. Eur Radiol
2011;21(12):2640–6.
[21] Boss E, Moolenaar S, Massuger L, et al. High-resolution proton
nuclear magnetic resonance spectroscopy of ovarian cyst ﬂuid.
NMR Biomed 2000;13:297–305.
[22] Baslow M. Evidence supporting a role for N-acetyl-L-aspartate as
a molecular water pump in myelinated neurons in the central
nervous system: an analytical review. Neurochem Int
2002;40:295–300.
[23] Baslow M. The existence of molecular water pumps in the
nervous system: a review of the evidence. Neurochem Int
1999;34:77–90.
[24] Kolwijck E, Engelke UF, Van Der Graaf M, et al. N-acetyl
resonances in in vivo and in vitro NMR spectroscopy of cystic
ovarian tumors. NMR Biomed 2009;22:1093–9.
[25] Mackinnon WB, Barry PA, Malycha PL, et al. Fine -needle
biopsy specimens of benign breast lesions distinguished from
invasive cancer ex vivo with proton MR spectroscopy. Radiology
1997;204:661–6.
[26] King King AD, Yeung DK, Ahuja AT, et al. In vivo 1H MR
spectroscopy of thyroid carcinoma. Eur J Radiol 2005;54:112–7.
106 L. El sorogy et al.[27] Stanwell P, Russell P, Carter J, et al. Evaluation of ovarian
tumors by proton magnetic resonance spectroscopy at three tesla.
Invest Radiol 2008;43:745–51.
[28] Pinker K, Stadlbauer A, Bogner W, et al. Molecular imaging
of cancer: MR spectroscopy and beyond. Eur J Radiol, in
press.
[29] Namimoto T, Awai K, Nakaura T, et al. Role of diffusion-
weighted imaging in the diagnosis of gynecological diseases. Eur
Radiol 2009;19(3):745–60.
[30] Fujii S, Kakite S, Nishihara K, et al. Diagnostic accuracy of
diffusion-weighted imaging in differentiating benign from malig-
nant ovarian lesions. J Magn Reson Imaging 2008;28:1149–56.[31] Thomassin-Naggara I, Dara E, Cuenod CA, et al. Contribu-
tion of diffusion-weighted MR imaging for predicting benig-
nity of complex adnexal masses. Eur Radiol 2009;19(6):
1544–52.
[32] Takeuchi M, Matsuzaki K, Nishitani H. Diffusion-weighted
magnetic resonance imaging of ovarian tumors: differentiation
of benign and malignant solid components of ovarian masses. J
Comput Assist Tomogr 2010;34(2):173–6.
[33] Bakir B, Bakan S, Tunaci M, et al. Diffusion-weighted imaging of
solid or predominantly solid gynaecological adnexial masses: is it
useful in the differential diagnosis? Br J Radiol 2011;84(1003):
600–11.
